Compare Supplements

Standard approved dosing is 140 mg subcutaneously every 2 weeks OR 420 mg subcutaneously once monthly, under a clinician. A prescription drug; this is informational, not a recommendation.

Any time

Subcutaneous prefilled autoinjector (evolocumab)

284 mg (300 mg inclisiran sodium) by subcutaneous injection administered by a healthcare professional on day 1, again at day 90 (month 3), then every 6 months thereafter. A prescription drug; this is the approved regimen, not a self-directed supplement protocol.

Any time

Prefilled subcutaneous injection (inclisiran 284 mg)

• Prior serious hypersensitivity reaction to evolocumab
• Use only under clinician direction as part of a lipid-management plan

• Statins
• Ezetimibe

• Known hypersensitivity to inclisiran or excipients
• Not a substitute for a clinician's evaluation — prescription drug only

• Statins / ezetimibe
• PCSK9 monoclonal antibodies (evolocumab / alirocumab)